Rene Van Der Merwe
BioPharmaceuticals R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
Journal: Journal of clinical pharmacology
Published: October 16, 2020
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: September 18, 2020
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: August 18, 2020
Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab.
Journal: International journal of chronic obstructive pulmonary disease
Published: December 14, 2018
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Journal: The Journal of allergy and clinical immunology
Published: February 07, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
Journal: Journal of the American Academy of Dermatology
Published: January 31, 2018
Tezepelumab in Adults with Uncontrolled Asthma.
Journal: The New England journal of medicine
Published: September 07, 2017
Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates .
Journal: International journal of clinical pharmacology and therapeutics
Published: June 08, 2017
A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.
Journal: Respiratory research
Published: May 19, 2017
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
Journal: Gastroenterology
Published: September 13, 2016
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Journal: The Lancet. Respiratory medicine
Published: October 13, 2014
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Journal: The Lancet. Respiratory medicine
Published: September 12, 2014
Last Updated: 09/26/2026